Actively Recruiting
Lopinavir/Ritonavir in PLWH With High-Grade AIN
Led by University of Wisconsin, Madison · Updated on 2026-04-22
21
Participants Needed
1
Research Sites
127 weeks
Total Duration
On this page
Sponsors
U
University of Wisconsin, Madison
Lead Sponsor
W
Wisconsin Partnership Program
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is being done to assess the safety of lopinavir/ritonavir in patients with PLWH with AIN. 30 participants will be recruited and can expect to be on active study for approximately 3 months and long term follow up for 40 weeks.
CONDITIONS
Official Title
Lopinavir/Ritonavir in PLWH With High-Grade AIN
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing to provide informed consent
- 18 years of age or older
- Diagnosis of biopsy-confirmed high-grade anal intraepithelial neoplasia (HGAIN)
- Willing to comply with all study procedures
You will not qualify if you...
- Diagnosis of low-grade anal dysplasia (AIN low-grade squamous intraepithelial lesion) by high-resolution anoscopy
- CD4 count less than 200 cells/mm³ at time of consideration for study entry
- Unable to provide informed consent
- Pregnant or breastfeeding female
- Currently receiving systemic chemotherapy or radiation therapy for another cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UW Digestive Health Center Anoscopy Clinic
Madison, Wisconsin, United States, 53705
Actively Recruiting
Research Team
C
Cancer Connect, MD, FACS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
PREVENTION
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here